Drug Profile
Venanprubart - Eli Lilly and Company
Alternative Names: BTLA agonist antibody - Eli Lilly and Company; BTLA mAb agonist - Eli Lilly and Company; LY-3361237Latest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Anti-inflammatories; Antibodies; Antipsoriatics
- Mechanism of Action BTLA protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Systemic lupus erythematosus
- Phase I Psoriasis
Most Recent Events
- 29 Dec 2023 Eli Lilly and Company completes a phase II trial in Systemic Lupus Erythematosus in USA, Argentina, Czechia Republic, France, Mexico, Poland, Peurto Rico, Taiwan (SC) (NCT05123586)
- 23 Mar 2023 Stanford University plans a phase II trial for Sjogren's syndrome in October 2023 (SC) (NCT05781451)
- 29 Nov 2022 Eli Lilly and Company completes a phase-I trial in Psoriasis in Bulgaria, Poland, Slovakia and Hungary (SC) (NCT04975295)